<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991637</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-201807-004</org_study_id>
    <nct_id>NCT03991637</nct_id>
  </id_info>
  <brief_title>Non-Invasive Blood Test Cross-Validation Study</brief_title>
  <official_title>Remote Sensing Comprehensive Metabolic Panel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Allen Jr.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Dakota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Concord Medical Technology Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study considers a cross-validation approach to determine the effectiveness of a
      non-invasive comprehensive metabolic panel (NICMP), relative to the venipuncture method. The
      NICMP machine learned powered device utilizes a light sensor to capture readings from either
      palm. The study (n=90) proves an agreement and strong correlation with respect to the NICMP
      and venipuncture blood draw.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Actual">March 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 11, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of Non-Invasive Comprehensive Metabolic Panel</measure>
    <time_frame>2-minutes</time_frame>
    <description>Determine the effectiveness, in terms of accuracy, of the NICMP against the venipuncture CMP (i.e. reference value).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Reproducibility of Results</condition>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>NICMP Spectral Reading</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-invasive spectral data is collected from this arm to function as the intervention of interest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venipuncture CMP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A standard CMP blood draw is performed to function as the &quot;gold standard&quot; reference value.
Specifically, the outcome of the experimental arm is cross-validated against the active comparator arm to determine the NICMP accuracy, relative to the venipuncture method.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-Invasive Comprehensive Metabolic Panel</intervention_name>
    <description>The device utilizes spectroscopy and machine learning to detect metabolic analyte concentrations.</description>
    <arm_group_label>NICMP Spectral Reading</arm_group_label>
    <arm_group_label>Venipuncture CMP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undiagnosed population

        Exclusion Criteria:

          -  Diagnosed population, pregnant women, mental heath/disabled, prisoners, fetus or
             deceased
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Altru Health System</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 1, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>June 20, 2019</last_update_submitted>
  <last_update_submitted_qc>June 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Concord Medical Technology Corporation</investigator_affiliation>
    <investigator_full_name>Joseph Allen Jr.</investigator_full_name>
    <investigator_title>Chief Executive Officer/Biomedical Engineer</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

